Brief: Alligator Bioscience Announces Positive Interim Results From Phase 2 Trial
Jan 3 (Reuters) - Alligator Bioscience AB ATORX.ST :
* SAID ON MONDAY, ALLIGATOR BIOSCIENCE ANNOUNCES POSITIVE
INTERIM
RESULTS FROM MITAZALIMAB OPTIMIZE-1 PHASE 2 TRIAL IN PANCREATIC
CANCER
* INTERIM RESULTS DEMONSTRATE OBJECTIVE RESPONSE RATE OF 52%
IN 23
EVALUABLE PATIENTS
Source text for Eikon: urn:newsml:reuters.com:*:nMFN1XxJZB
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue